Richard Klausner

CIK: 0001591178

Transaction Breakdown

Open Market Buys (P)1 (25.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

LYEL

Lyell Immunopharma, Inc.

Director

PBLS

Parabilis Medicines, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

LYEL
Lyell Immunopharma, Inc.
Jun 10, 2026
Award(A)
Option (right to buy)
Direct
9.3K shares-
PBLS
Parabilis Medicines, Inc.
Jun 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
20.2K shares-
LYEL
Lyell Immunopharma, Inc.
May 15, 2025
Award(A)
Option (right to buy)
Direct
130K shares-
LYEL
Lyell Immunopharma, Inc.
Mar 14, 2025
Purchase(P)
Indirect
158K shares at avg. $0.60$95K

		Type	Shares	Price		Ownership
Jun 10, 2026	LYEL Lyell Immunopharma, Inc.	Award(A) Option (right to buy)	9,250	-	-	Direct
Jun 9, 2026	PBLS Parabilis Medicines, Inc.	Award(A) Stock Option (Right to Buy)	20,215	-	-	Direct
May 15, 2025	LYEL Lyell Immunopharma, Inc.	Award(A) Option (right to buy)	130,000	-	-	Direct
Mar 14, 2025	LYEL Lyell Immunopharma, Inc.	Purchase(P)	158,000	$0.60	$94,942	Indirect

1-4 of 4 transactions

About Klausner Richard

Klausner Richard (SEC CIK 0001591178) files insider reports with the SEC as Director of Lyell Immunopharma, Inc. (LYEL) and Director of Parabilis Medicines, Inc. (PBLS).

Signal8 holds 5 ownership filings by Klausner Richard (1 Form 3, 4 Form 4), filed between Mar 18, 2025 and Jun 12, 2026. Those filings report 4 transactions, from Mar 14, 2025 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Klausner Richard's filings is in CAMBRIDGE, MA.

Recent filings by Klausner Richard

Jun 10, 2026: Grant or award of LYEL derivative securities (Form 4, code A).
Jun 9, 2026: Grant or award of PBLS derivative securities (Form 4, code A).
May 15, 2025: Grant or award of LYEL derivative securities (Form 4, code A).
Mar 14, 2025: Open-market purchase of LYEL shares (Form 4, code P).

Other insiders filing for Lyell Immunopharma, Inc. (LYEL)

Aguirre Jarrad Mattieu, Chief Medical Officer
Shook David, Chief Medical Officer
Seely Lynn, President and CEO
Hill Stephen J., Chief Operating Officer
Lee Gary K., Chief Scientific Officer
Bulis Veronica Sanchez, VP, Corporate Controller

How to read Form 4 transaction codes